Zobrazeno 1 - 10
of 64
pro vyhledávání: '"David A Knorr"'
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/31a08e8d721941fe8a4dc5e2878082aa
Autor:
Shabari Mangalore Shenoy, Thomas Di Vitantonio, Anna Plitt, Rocio Perez-Johnston, Jillian Gutierrez, David A. Knorr, Eytan M. Stein, Jennifer E. Liu, Stephanie Feldman
Publikováno v:
Cardio-Oncology, Vol 7, Iss 1, Pp 1-4 (2021)
Abstract Background All trans retinoic acid (ATRA) has revolutionized the treatment and outcomes of patients with Acute Promyelocytic Leukemia (APL). Induction therapy with ATRA is associated with the rare but potentially fatal complication of differ
Externí odkaz:
https://doaj.org/article/7a32f9335a8a4ac5b0c141e82e7328e5
Autor:
Ramin Sedaghat Herati, David A. Knorr, Laura A. Vella, Luisa Victoria Silva, Lakshmi Chilukuri, Sokratis A. Apostolidis, Alexander C. Huang, Alexander Muselman, Sasikanth Manne, Oliva Kuthuru, Ryan P. Staupe, Sharon A. Adamski, Senthil Kannan, Raj K. Kurupati, Hildegund C. J. Ertl, Jeffrey L. Wong, Stylianos Bournazos, Suzanne McGettigan, Lynn M. Schuchter, Ritesh R. Kotecha, Samuel A. Funt, Martin H. Voss, Robert J. Motzer, Chung-Han Lee, Dean F. Bajorin, Tara C. Mitchell, Jeffrey V. Ravetch, E. John Wherry
Publikováno v:
Nature Immunology. 23:1183-1192
Anti-programmed death-1 (anti-PD-1) immunotherapy reinvigorates CD8 T cell responses in patients with cancer but PD-1 is also expressed by other immune cells, including follicular helper CD4 T cells (Tfh) which are involved in germinal centre respons
Autor:
David A. Knorr, Santosha A. Vardhana, Alexander M. Lesokhin, Sham Mailankody, Malin Hultcrantz, Lindsey E. Roeker, Anthony R. Mato, Mini Kamboj, Genovefa A. Papanicolaou, Christina D. Bravo, Lauren Margetich, Saddia Momotaj, Saumya Sharan, Edith Serrano, Sawsan R. Boutemine, Jennifer C. Young, LeeAnn T. Marcello, Elizabeth Hoover, Melissa S. Pessin, Sital Doddi, Lakshmi V. Ramanathan, Sean M. Devlin, Gunjan L. Shah, David J. Chung
Coronavirus disease-19 (COVID-19) vaccine response data for patients with hematologic malignancy, who carry high risk for severe COVID-19 illness, are incomplete. In a study of 551 hematologic malignancy patients with leukemia, lymphoma, and multiple
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cd3f011a96e082689cce3d71e6c5300e
https://doi.org/10.1158/2643-3230.c.6550494.v1
https://doi.org/10.1158/2643-3230.c.6550494.v1
Autor:
Gunjan L. Shah, David J. Chung, Miguel Angel Perales, Mini Kamboj, Genovefa A. Papanicolaou, Christina D. Bravo, Meighan Palazzo, Erica Dunn, Melissa S. Pessin, Lakshmi V. Ramanathan, Sean M. Devlin, Sital Doddi, LeeAnn T. Marcello, Jennifer C. Young, Santosha A. Vardhana, David A. Knorr, Ioannis Politikos, Roni Tamari
3A: Anti-SARS-CoV-2 spike IgG titers by different cutoffs Supplemental Table 3B: Neutralization Ab >30% threshold when using different cutoffs of anti-SARS-CoV-2 spike IgG response
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4102806eb19a89e3ddae0086ece2d310
https://doi.org/10.1158/2643-3230.22543740.v1
https://doi.org/10.1158/2643-3230.22543740.v1
Autor:
Gunjan L. Shah, David J. Chung, Miguel Angel Perales, Mini Kamboj, Genovefa A. Papanicolaou, Christina D. Bravo, Meighan Palazzo, Erica Dunn, Melissa S. Pessin, Lakshmi V. Ramanathan, Sean M. Devlin, Sital Doddi, LeeAnn T. Marcello, Jennifer C. Young, Santosha A. Vardhana, David A. Knorr, Ioannis Politikos, Roni Tamari
50 Anti-SARS-CoV-2 spike IgG, 30 Neutralizing antibodies
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::24a3a96ed4be1aa4a739e7762dbe74d7
https://doi.org/10.1158/2643-3230.22543746.v1
https://doi.org/10.1158/2643-3230.22543746.v1
Autor:
Gunjan L. Shah, David J. Chung, Miguel Angel Perales, Mini Kamboj, Genovefa A. Papanicolaou, Christina D. Bravo, Meighan Palazzo, Erica Dunn, Melissa S. Pessin, Lakshmi V. Ramanathan, Sean M. Devlin, Sital Doddi, LeeAnn T. Marcello, Jennifer C. Young, Santosha A. Vardhana, David A. Knorr, Ioannis Politikos, Roni Tamari
Cellular therapies including allogeneic hematopoietic cell transplant (allo-HCT) and autologous hematopoietic cell transplant (auto-HCT) and chimeric antigen receptor (CAR) T-cell therapy render patients severely immunocompromised for extended period
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::51c02005b504fc6da5f86adbfdedca32
https://doi.org/10.1158/2643-3230.c.6550392
https://doi.org/10.1158/2643-3230.c.6550392
Autor:
Gunjan L. Shah, David J. Chung, Miguel Angel Perales, Mini Kamboj, Genovefa A. Papanicolaou, Christina D. Bravo, Meighan Palazzo, Erica Dunn, Melissa S. Pessin, Lakshmi V. Ramanathan, Sean M. Devlin, Sital Doddi, LeeAnn T. Marcello, Jennifer C. Young, Santosha A. Vardhana, David A. Knorr, Ioannis Politikos, Roni Tamari
2A- MVA for the whole cohort 2B-MVA for patients who underwent allo-HCT only
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::30b7f7abaad27b42864701288586922a
https://doi.org/10.1158/2643-3230.22543743
https://doi.org/10.1158/2643-3230.22543743
Autor:
Scott Parker, Charlotte McDowall, Luis Sanchez-Perez, Cristina Osorio, Patrick C. Duncker, Aaron Briley, Adam M. Swartz, James E. Herndon, Yen-Rei A. Yu, Roger E. McLendon, Thomas F. Tedder, Annick Desjardins, David M. Ashley, Michael Dee Gunn, David S. Enterline, David A. Knorr, Ira H. Pastan, Smita K. Nair, Darell D. Bigner, Vidyalakshmi Chandramohan
Publikováno v:
Science Translational Medicine. 15
D2C7-immunotoxin (IT), a dual-specific IT targeting wild-type epidermal growth factor receptor (EGFR) and mutant EGFR variant III (EGFRvIII) proteins, demonstrates encouraging survival outcomes in a subset of patients with glioblastoma. We hypothesiz
Autor:
Jeffrey L. Wong, Patrick Smith, Juan Angulo-Lozano, Daniel Ranti, Bernard H. Bochner, John P. Sfakianos, Amir Horowitz, Jeffrey V. Ravetch, David A. Knorr
CD40 is a central co-stimulatory receptor implicated in the development of productive anti-tumor immune responses across multiple cancers, including bladder cancer. Despite strong preclinical rationale, systemic administration of therapeutic agonisti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::10a89de64af520477f2a962704e8fbd0
https://doi.org/10.1101/2023.01.30.526266
https://doi.org/10.1101/2023.01.30.526266